Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

NCT06494150 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT06494150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06494150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 26, 2024
Completion date
September 30, 2029
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

low grade ovarian serous adenocarcinoma